PureFacts Financial Solutions acquires Quartal Financial Solutions to become a global WealthTech leader
PureFacts Financial Solutions, a leading WealthTech provider of fees, reporting and AI-powered predictive analytics solutions, has acquired Quartal Financial Solutions, Europe’s leading provider of fee billing and commission solutions for the financial and insurance industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117006164/en/
PureFacts Financial Solutions acquires Quartal Financial Solutions (Graphic: Business Wire)
This acquisition further strengthens PureFacts’ ability to provide mission critical, AI-driven and regulatory compliant fee solutions to its marquee clients. Additionally, the combined organization expands the company’s global reach to bring market-leading solutions and opportunities to all its stakeholders.
These two successful companies both have industry-leading expertise in calculating fees and commissions. Together, they will provide the most powerful fee platform in the global financial marketplace. The combined entity will benefit from strengthening their core capabilities in data aggregation, machine learning and financial industry expertise.
This is the second successful acquisition completed by PureFacts this year, coming on the heels of its acquisition of CRM consulting firm, VennScience in May 2020. Led by Gerard Daniels, PureFacts Head of Corporate Development and supported by world class advisors including PricewaterhouseCoopers Corporate Finance Inc. and Goodmans LLP, the team continues to identify strategic acquisitions that best serve its clients and accelerate PureFacts’ strategy.
PureFacts global head office will remain in Toronto, Canada while the European head office will be located at Quartal’s office in Zurich, Switzerland. PureFacts CEO Robert Madej will take the helm of the new corporate entity, with PureFacts President Rajini McRae expanding her role to include the global businesses. Quartal CEO Thierry Zuppinger has been appointed as the General Manager Europe and Asia for the combined entity.
“With any acquisition or partnership that we undertake, we always ensure our values are aligned and our clients’ interests are at the centre,” says Robert Madej, PureFacts CEO. “In this case, we are further excited by the Quartal team’s enthusiasm and the willingness of the key executive team to become shareholders in PureFacts.”
“We are thrilled about the combination of our businesses and are looking forward to working with Rob and his team, who have proven to be a perfect fit as a strategic partner to Quartal’s business going forward,” says Thierry Zuppinger, CEO of Quartal Financial Solutions. “Joining forces with PureFacts will significantly accelerate our joint journey to becoming a truly global market and mindshare leader in the fee and commission management domain; allowing us to better service our clients globally.”
Quartal Financial Solutions is a market-leading provider of fee and commission management, and revenue and expense lifecycle management software for the financial and insurance industries. The company was founded in 1999 and currently has more than 30 clients with over 50 software installations in 15 countries across Europe, United States, Middle East, Africa, and the Asia-Pacific region. Their clients enjoy reduced operating costs, higher performances, quick Return on Investment, and reduced technology obsolescence through the use of their technologically advanced solutions. www.quartalfs.com
Ranked a WealthTech100 Company and Top 12 Canadian Innovator, PureFacts Financial Solutions provides wealth management solutions for the financial services industry in Canada, the USA, and Europe. PureFacts’ mission is to create meaningful wealth solutions that help people live their best lives. They provide their clients with transformational WealthTech solutions to future-proof their business and accelerate growth by leveraging their expertise in wealth management data aggregation, complex calculations, Artificial Intelligence and machine learning. www.purefacts.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117006164/en/
Contact information
Mr. Gerard Daniels
Head of Corporate Development, PureFacts
gerard.daniels@purefacts.com
Mr. Thierry Zuppinger
CEO, Quartal Financial Solutions
thierry.zuppinger@quartalfs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom